^
    Back
    Association details:
    Biomarker:HAS3 expression
    Cancer:Renal Cell Carcinoma
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) +
    Cantabilin (4-methylumbelliferone) (Hyaluronic acid synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ADA 2020
    Title:

    MP08-17: Biomarker-targeted novel combination for renal cell carcinoma

    Published date:
    05/15/2020
    Excerpt:
    MU synergized with SF to inhibit RCC cell and primary tumor spheroid proliferation > 90%, motility/invasion (>80%) and induced apoptosis (5-fold). Combination of MU (0.1, 0.2 mM) with SF (5 µM) downregulated (>80%) HAS3 expression, HAS3 promoter activity and HA synthesis in RCC cells. While HAS3 transfectants were resistant to SF+MU treatment, HAS3-KO transfectants were sensitive to SF alone.